

May 22, 2018



To,

<b>BOMBAY STOCK EXCHANGE LIMITED</b>  Phiroze Jeejeebhoy Tower, Dalal Street, Fort, Mumbai – 400 001  <b>Scrip Code : 532908</b>	<b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b>  Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051  <b>Scrip ID : SHARONBIO</b>
--	--

Dear Sir/Madam,

**Sub: Notice to consider and approve Audited Financial Results for the quarter and year ended March 31, 2018**

We hereby inform you that Corporate Insolvency Resolution Process (“CIRP”) was initiated in respect of Sharon Bio-Medicine Limited (“the Company”) under the provisions of Insolvency and Bankruptcy Code, 2016 (“IBC”) by an order of National Company Law Tribunal (“NCLT”) with effect from April 11, 2017. Further to the same Resolution Plan submitted by Peter Beck and Partners has been approved by NCLT vide order dated March 08, 2018.

Pursuant to Regulation 29(1) (a) of the SEBI (Listing obligations and disclosure requirements) Regulations 2015, Audited Financial Results of the Company will be considered and approved for the quarter and year ended March 31, 2018 on Wednesday May 30, 2018 at the corporate office of the Company at C-310/312, BSEL Tech Park, Opp. Vashi Railway Station, Navi Mumbai-400703 at 2:00 P.M.

In connection with the above, as per the company's code of conduct to regulate, monitor and report trading by insiders, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the Company will be closed from May 23, 2018 to June 01, 2018 (both days inclusive) for the purpose of declaration of financial results of the Company for the quarter and year ended on March 31, 2018. Accordingly, all the Designated Employees of the Company have been intimated not to enter into any transaction involving the securities of the Company during the aforesaid period of closure of trading window.

Further, please note that the Company has already made necessary arrangement to publish the same in the newspaper as required under SEBI (LODR), Regulations, 2015.

This is for your information and record.

For Sharon Bio-Medicine Limited

  
Deepal Bhatia  
Company Secretary & Compliance Officer



Adm. Off. : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705.  
Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001  
[www.sharonbio.com](http://www.sharonbio.com)

CIN NO. L24110MH1989PLC052251

*Caring for relationships*



# **Sharon**

**BIO-MEDICINE LTD.**

CIN:L24110MH1989PLC052251

Regd. Off.: W-34 & W-34/1, MIDC, Taloja, Dist-raigad.

Tel No.91-22 67944000 Fax No.91-22 67944001

Email:finance@sharonbio.com,

Web:www.sharonbio.com

## **NOTICE**

Notice is hereby given that pursuant to Regulation 47(1) (a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Company will consider and approve the Audited Financial Results for the Quarter and Year ended March 31, 2018 on Wednesday, May 30, 2018 at 02.00 PM.

Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window in respect of dealing in the Equity Shares of the Company, will remain closed, for all the Directors, Designated (specified) Employees of the Company and "connected persons" with the Company, with effect from May 23, 2018 to June 01, 2018 (both days inclusive).

Further details will also be available on website of the Company i.e. www.sharonbio.com as well as website of the Stock Exchanges www.nseindia.com & www.bseindia.com

**By Sharon Bio-Medicine Ltd.**

**Sd/-**

**Deepali Bhatia**

**Date: May 22, 2018**

**Company Secretary  
& Compliance Officer**

**Place: Mumbai**